Kick away your problems by advanced treatment in lung cancer.

Lung cancer is one of the leading cancers of death among all the cancers worldwide and it is developed through various processes which are involving development of numerous genetic and epigenetic modifications, mainly the inhibition of tumor suppressor pathways and also the activation of growth promoting pathways. Lung cancer is sub-divided in to two categories: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Lung cancer can be easily treated with the help of immunotherapy. There are several immunotherapeutic of monoclonal Antibody Drug Conjugate, kinase inhibitor drugs, and antibody drug conjugates are available for the treatment with strong activity against the tumors. 

www.gapsos.com

American Cancer Society estimates around 221,200 new cases (115,610 males and 105,590 females) and approximately 158,040 deaths (86,380 males and 71,660 females) due to lung cancer in the United States in 2015. Lung cancer is responsible for 27% deaths among all the cancers and it represents 13.5% of all cancer. The age- standardized rate of incidence and mortality rates varies varied between 3-35 per 100,000 in females, and 21-77 per 100,000 in males and 8-19 per 100,000 in females and 32-52 per 100,000 in males. The most common sign and symptoms of lung cancer are persistent cough, chest pain, voice change, hemoptysis, and recurrent pneumonia or bronchitis. The important risk factors of lung cancer are radiation exposure, industrial substances, radon gas, tuberculosis, air pollution, asbestos, genetics, and smoking and smoking tobacco is other important risk factor of lung cancer and around 87% lung cancer occurs in the United States due to smoking. 

The lung cancer can be diagnose through various imaging techniques such as CT scan and other techniques for the diagnosis of lung cancer are sputum cytology and various biopsy test of blood. There are various radiation therapies, surgical operations, and numerous FDA approved chemotherapeutic drugs for the treatment of lung cancer but these therapies are costly and also having various side-effects for the patients during the treatment or after the treatment.

The immunotherapy is single option which is having minor side-effects for the patients because it enhances the immune system and kills the cancerous cells. The monoclonal antibodies, immune combination therapy, kinase inhibitor drugs, and antibody drug conjugates are having various immunotherapeutic which is having high potency to fight against the cancerous cells. The Bevacizumab, Erlotinib, Afatinib, Gefitinib, and Crizotinib are most commonly used for the treatment of lung cancer and several drugs are under clinical trials for FDA approval. These immunotherapeutic indicates the potential of immunotherapy in the treatment of lung cancer against the other treatments.